Welcome to our dedicated page for Orchard Therapeutics Plc news (Ticker: ORTX), a resource for investors and traders seeking the latest updates and insights on Orchard Therapeutics Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Orchard Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Orchard Therapeutics Plc's position in the market.
Orchard Therapeutics (Nasdaq: ORTX) reported progress in its gene therapy programs for neurometabolic disorders, with key updates on Libmeldy (OTL-200) for MLD and OTL-203 for MPS-I. The company submitted responses to EMA regarding Libmeldy's marketing application and received FDA designations for OTL-203. Financially, Orchard reported Q2 2020 R&D expenses of $31.6 million, down from $40.5 million in Q2 2019. The net loss for the quarter was $47.5 million, slightly improved from $50.5 million year-over-year. With $228.7 million in cash, the company expects to fund operations into 2022.
Orchard Therapeutics (Nasdaq: ORTX) has received orphan drug and rare pediatric disease designations from the FDA for its gene therapy OTL-203, aimed at treating mucopolysaccharidosis type I (MPS-I). This recognition highlights the urgent need for therapeutic options for MPS-I patients. The designations afford benefits such as tax credits for clinical testing and market exclusivity. Early trial data indicates successful hematologic engraftment in eight patients. Full results and a registrational study are expected to be announced in 2021.
Orchard Therapeutics (Nasdaq: ORTX) has entered into two royalty-bearing license agreements with GlaxoSmithKline for their lentiviral stable cell line technology, enhancing its hematopoietic stem cell gene therapies for Wiskott Aldrich syndrome and transfusion-dependent beta thalassemia. This technology promises efficient viral vector production, reducing costs and production time, potentially providing a competitive advantage. Orchard plans to submit biologics license applications for OTL-103 in 2021, though the licensing terms won't materially impact its financial position or cash needs.
Orchard Therapeutics (Nasdaq: ORTX) announced positive interim results from its ongoing clinical trial for OTL-203, an ex vivo gene therapy for mucopolysaccharidosis type I (MPS-I). All eight patients treated achieved hematologic engraftment within 45 days, marking a primary outcome measure. Significant improvements were observed in motor skills and cognitive functions in the first two patients, with continued normal growth. The company anticipates initiating a registrational trial in 2021 and plans to report more interim results later in 2020.
Summary not available.
Summary not available.
Summary not available.